A number of firms have modified their ratings and price targets on shares of Catalent (NASDAQ: CTLT) recently:

  • 9/15/2017 – Catalent was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
  • 9/12/2017 – Catalent is now covered by analysts at Needham & Company LLC. They set a “hold” rating and a $42.00 price target on the stock.
  • 9/8/2017 – Catalent was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 9/7/2017 – Catalent was upgraded by analysts at ValuEngine from a “hold” rating to a “buy” rating.
  • 9/1/2017 – Catalent was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Catalent, Inc. provides advanced delivery technologies and development solutions for drugs, biologics and consumer health products. It operates through Oral Technologies, Medication Delivery Solutions, and Development & Clinical Services. The Oral Technologies segment address the full diversity of the pharmaceutical industry including small molecules, large molecule biologics and consumer health products. The Medication Delivery Solutions segment offers formulation, development, and manufacturing services for delivery of drugs and biologics administered through injection, inhalation, and ophthalmic routes. The Development and Clinical Services segment provides manufacturing, packaging, storage, and inventory management services for drugs and biologics in clinical trials. Catalent, Inc. is headquartered in Somerset, New Jersey. “
  • 8/31/2017 – Catalent had its “outperform” rating reaffirmed by analysts at Wells Fargo & Company. They now have a $39.00 price target on the stock, up previously from $30.00.
  • 8/29/2017 – Catalent had its “buy” rating reaffirmed by analysts at Piper Jaffray Companies. They now have a $45.00 price target on the stock.
  • 8/29/2017 – Catalent had its “buy” rating reaffirmed by analysts at J P Morgan Chase & Co. They now have a $40.00 price target on the stock.
  • 8/29/2017 – Catalent had its “hold” rating reaffirmed by analysts at Jefferies Group LLC. They now have a $38.00 price target on the stock, up previously from $35.00.
  • 8/29/2017 – Catalent had its “ourperform” rating reaffirmed by analysts at William Blair.
  • 8/29/2017 – Catalent had its “buy” rating reaffirmed by analysts at Bank of America Corporation. They now have a $40.00 price target on the stock, up previously from $38.00.
  • 8/22/2017 – Catalent was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $39.00 price target on the stock. According to Zacks, “Catalent, Inc. provides advanced delivery technologies and development solutions for drugs, biologics and consumer health products. It operates through Oral Technologies, Medication Delivery Solutions, and Development & Clinical Services. The Oral Technologies segment address the full diversity of the pharmaceutical industry including small molecules, large molecule biologics and consumer health products. The Medication Delivery Solutions segment offers formulation, development, and manufacturing services for delivery of drugs and biologics administered through injection, inhalation, and ophthalmic routes. The Development and Clinical Services segment provides manufacturing, packaging, storage, and inventory management services for drugs and biologics in clinical trials. Catalent, Inc. is headquartered in Somerset, New Jersey. “
  • 8/18/2017 – Catalent was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Catalent, Inc. provides advanced delivery technologies and development solutions for drugs, biologics and consumer health products. It operates through Oral Technologies, Medication Delivery Solutions, and Development & Clinical Services. The Oral Technologies segment address the full diversity of the pharmaceutical industry including small molecules, large molecule biologics and consumer health products. The Medication Delivery Solutions segment offers formulation, development, and manufacturing services for delivery of drugs and biologics administered through injection, inhalation, and ophthalmic routes. The Development and Clinical Services segment provides manufacturing, packaging, storage, and inventory management services for drugs and biologics in clinical trials. Catalent, Inc. is headquartered in Somerset, New Jersey. “
  • 8/16/2017 – Catalent was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 8/1/2017 – Catalent was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 7/21/2017 – Catalent had its “buy” rating reaffirmed by analysts at Bank of America Corporation. They now have a $38.00 price target on the stock, up previously from $37.00.

Shares of Catalent Inc (NASDAQ:CTLT) traded down 2.96% during mid-day trading on Tuesday, reaching $38.72. 1,036,707 shares of the company’s stock were exchanged. The company has a 50 day moving average price of $37.07 and a 200 day moving average price of $33.66. Catalent Inc has a 52-week low of $21.83 and a 52-week high of $42.22. The firm has a market cap of $4.85 billion and a P/E ratio of 44.51.

Catalent (NASDAQ:CTLT) last issued its quarterly earnings results on Monday, August 28th. The company reported $0.65 EPS for the quarter, topping the Zacks’ consensus estimate of $0.57 by $0.08. The firm had revenue of $616.90 million for the quarter, compared to analyst estimates of $547.48 million. Catalent had a net margin of 10.02% and a return on equity of 36.29%. The business’s revenue for the quarter was up 15.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.52 EPS. Analysts forecast that Catalent Inc will post $1.61 earnings per share for the current fiscal year.

In other news, SVP Christine Dolan sold 745 shares of the stock in a transaction on Tuesday, August 1st. The shares were sold at an average price of $34.85, for a total value of $25,963.25. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.

Receive News & Ratings for Catalent Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent Inc and related companies with MarketBeat.com's FREE daily email newsletter.